| BCL6 is a negative prognostic factor and exhibits pro-oncogenic activity in ovarian cancer. | ovarian, |
| Taken together, our results demonstrated that miR-187-3p played a pivotal role on NSCLC through inhibiting cell proliferation, migration, invasion, and promoting apoptosis by targeting oncogenic BCL6. | lung, |
| Overexpressed BCL6 (LAZ3) oncoprotein triggers apoptosis, delays S phase progression and associates with replication foci. | None |
| Colocalization and heteromerization between the two human oncogene POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF. | None |
| Target genes downregulated by the BCL-6/LAZ3 oncoprotein in mouse Ba/F3 cells. | None |
| Regulation of gene expression by the proto-oncogene BCL-6. | None |
| The proto-oncogene BCL-6 in normal and malignant B cell development. | None |
| This study suggest translocation-mediated BCL6 oncogene activation as a so far unknown pathogenetically relevant mechanism in PCNSL. | None |
| The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. | None |
| The proto-oncogene BCL-6 is expressed in olfactory sensory neurons. | None |
| The proto-oncogene BCL6, a potential target of miR-127, was translationally downregulated after treatment with the chromatin-modifying drugs. | None |
| Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. | None |
| Genotoxic stress regulates expression of the proto-oncogene Bcl6 in germinal center B cells. | None |
| Inhibition of interleukin-1beta-induced group IIA secretory phospholipase A2 expression by peroxisome proliferator-activated receptors (PPARs) in rat vascular smooth muscle cells: cooperation between PPARbeta and the proto-oncogene BCL-6. | None |
| The proto-oncogene BCL6 promotes survival of olfactory sensory neurons. | None |
| A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. | None |
| An oncogenic role for alternative NF-kappaB signaling in DLBCL revealed upon deregulated BCL6 expression. | None |
| findings uncover MLL-dependent transcriptional activation of BCL6 as a previously unrecognized requirement of malignant transformation by oncogenic MLL fusions and identified BCL6 as a novel target for the treatment of MLL-rearranged B-ALL. | None |
| The BTB/POZ domain targets the LAZ3/BCL6 oncoprotein to nuclear dots and mediates homomerisation in vivo. | None |
| Transcriptional repression by the proto-oncogene BCL-6. | None |